TY - JOUR
T1 - Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model
AU - Miyake, Kentaro
AU - Kiyuna, Tasuku
AU - Miyake, Masuyo
AU - Kawaguchi, Kei
AU - Zhang, Zhiying
AU - Wangsiricharoen, Sintawat
AU - Razmjooei, Sahar
AU - Oshiro, Hiromichi
AU - Higuchi, Takashi
AU - Li, Yunfeng
AU - Nelson, Scott D.
AU - Murakami, Takashi
AU - Hiroshima, Yukihiko
AU - Kumamoto, Takafumi
AU - Matsuyama, Ryusei
AU - Bouvet, Michael
AU - Singh, Shree Ram
AU - Chawla, Sant P.
AU - Endo, Itaru
AU - Hoffman, Robert M.
N1 - Publisher Copyright:
© 2019
PY - 2019/2/19
Y1 - 2019/2/19
N2 - There are no effective treatments for leiomyosarcoma (LMS) spreading intraabdominally. The aim of this study was to develop precision chemotherapy for recurrent peritoneal LMS metastases in a patient-derived orthotopic xenograft (PDOX) model. The LMS PDOX models were established orthotopically on the dome of the bladder of nude mice. The LMS PDOX models were randomized into 6 groups when the tumor volume reached 80 mm 3 : G1: untreated control; G2: doxorubicin (DOX) (DOX: i.p., 3 mg/kg, weekly, 3 weeks); G3: DOX combined with olaratumab (OLA) (DOX: i.p., 3 mg/kg, weekly, 3 weeks; OLA: i.p., 40 mg/kg, 3 times/week, 3 weeks); G4: gemcitabine (GEM) combined with docetaxel (DOC) (GEM: i.p., 100 mg/kg, weekly, 3 weeks; DOC: i.p., 20 mg/kg, weekly, 3 weeks); G5: pazopanib (PAZ) (PAZ: p.o., 100 mg/kg, daily, 3 weeks); G6: palbociclib (PAL) (PAL: p.o., 100 mg/kg, daily, 3 weeks). All mice were sacrificed on day 22. Body weight was assessed twice a week. Tumor volume was measured on day 0 and day 22. Although all regimens had a significant efficacy compared to the untreated group (P < 0.001), only GEM combined with DOC regressed the tumor significantly (P < 0.001), suggesting GEM combined with DOC has clinical potential for this LMS patient.
AB - There are no effective treatments for leiomyosarcoma (LMS) spreading intraabdominally. The aim of this study was to develop precision chemotherapy for recurrent peritoneal LMS metastases in a patient-derived orthotopic xenograft (PDOX) model. The LMS PDOX models were established orthotopically on the dome of the bladder of nude mice. The LMS PDOX models were randomized into 6 groups when the tumor volume reached 80 mm 3 : G1: untreated control; G2: doxorubicin (DOX) (DOX: i.p., 3 mg/kg, weekly, 3 weeks); G3: DOX combined with olaratumab (OLA) (DOX: i.p., 3 mg/kg, weekly, 3 weeks; OLA: i.p., 40 mg/kg, 3 times/week, 3 weeks); G4: gemcitabine (GEM) combined with docetaxel (DOC) (GEM: i.p., 100 mg/kg, weekly, 3 weeks; DOC: i.p., 20 mg/kg, weekly, 3 weeks); G5: pazopanib (PAZ) (PAZ: p.o., 100 mg/kg, daily, 3 weeks); G6: palbociclib (PAL) (PAL: p.o., 100 mg/kg, daily, 3 weeks). All mice were sacrificed on day 22. Body weight was assessed twice a week. Tumor volume was measured on day 0 and day 22. Although all regimens had a significant efficacy compared to the untreated group (P < 0.001), only GEM combined with DOC regressed the tumor significantly (P < 0.001), suggesting GEM combined with DOC has clinical potential for this LMS patient.
KW - Docetaxel
KW - Gemcitabine
KW - Leiomyosarcoma
KW - Nude mice
KW - PDOX
KW - Patient-derived orthotopic xenograft
UR - http://www.scopus.com/inward/record.url?scp=85060519506&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060519506&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2019.01.046
DO - 10.1016/j.bbrc.2019.01.046
M3 - Article
C2 - 30660363
AN - SCOPUS:85060519506
VL - 509
SP - 1041
EP - 1046
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
SN - 0006-291X
IS - 4
ER -